Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Inetetamab in advanced HER2-positive breast cancer
ChiCTR2200061413Phase 4Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of inetetamab in breast cancer, sponsored by Shandong Cancer Hospital. Primary endpoints: Progression Free Survival, Adverse Events and 6 more. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
inetetamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200061413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061413.